Immunic, Inc. (NASDAQ:IMUX) Short Interest Update

Immunic, Inc. (NASDAQ:IMUX) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 3,750,000 shares, an increase of 6.5% from the January 15th total of 3,520,000 shares. Based on an average trading volume of 925,600 shares, the days-to-cover ratio is presently 4.1 days.

Analysts Set New Price Targets

IMUX has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. HC Wainwright assumed coverage on Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 price target for the company. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, February 10th. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus target price of $12.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the period. HB Wealth Management LLC acquired a new stake in Immunic in the fourth quarter valued at approximately $81,000. State Street Corp lifted its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic in the 3rd quarter valued at approximately $50,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Stock Performance

Shares of NASDAQ:IMUX traded up $0.09 during trading on Tuesday, hitting $1.09. The company’s stock had a trading volume of 1,407,690 shares, compared to its average volume of 943,350. Immunic has a fifty-two week low of $0.92 and a fifty-two week high of $2.11. The business has a 50 day moving average price of $1.03 and a two-hundred day moving average price of $1.26. The company has a market capitalization of $98.19 million, a PE ratio of -0.89 and a beta of 1.87.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.